ATLANTA, Ga.
(January 30, 2024) - Nonprofit foundation Hop On A Cure, a leading advocate in the fight against ALS, is proud to announce its substantial investment in MitoSense, an innovative biotechnology firm specializing in mitochondrial therapies. This collaboration marks a significant step in advancing MitoSense's flagship technology, MOT™ (Mitochondria Organelle Transplantation), a promising new approach to ALS treatment.
Hop On A Cure was founded in 2022 by John Driskell Hopkins (Hop), and his wife Jennifer, following his diagnosis with ALS (commonly known as Lou Gehrig’s Disease) in 2021. Hopkins is a multi-GRAMMY® Award-winning founding member and songwriter of Zac Brown Band. With this rare platform in mind, Hopkins, along with his wife Jennifer, launched Hop On A Cure to increase ALS awareness and to raise funds to enable new research to find ways to treat this disease, which currently has no known cure.
MOT™, a novel therapeutic concept developed by MitoSense, leverages the unique capabilities of mitochondria to combat the progression of Amyotrophic Lateral Sclerosis (ALS). By directly transplanting healthy mitochondria into affected cells, MOT™ seeks to restore cellular function and slow down, or potentially reverse, the debilitating symptoms of ALS. This approach represents a groundbreaking shift in the battle against this relentless disease, offering hope where traditional treatments have seen limited success.
Van Hipp, Chairman of MitoSense, expressed his enthusiasm about the partnership: "With Hop On A Cure's support, we're poised to take a quantum leap in ALS treatment. MOT™ is not just a treatment; it's a beacon of hope for those affected by ALS. Together, we're charting a course towards a future where ALS is a manageable condition, not a terminal diagnosis."
Nic Shefrin from Hop On A Cure also shared their perspective: "Our investment in MitoSense and the development of MOT™ reflects our unwavering commitment to finding a cure for ALS. We believe that MOT™ holds the key to unlocking new, effective treatments, and we're excited to be part of this revolutionary journey."
This strategic investment will accelerate the clinical development of MOT™, bringing it closer to clinical application and potentially changing the ALS treatment landscape forever.
For more information, visit www.mitosenseinc.com.
